Biocardia stock.

SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Nov 8, 2023 · BioCardia Reports First Quarter 2023 Business Highlights and Financial Results. BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications. BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023. The Wall Street analyst predicted. that Biocardia's share price could reach $4.00 by Nov 14, 2024. The average Biocardia stock price prediction forecasts a potential upside of 495.24% from the current BCDA share price of $0.67. Nov 8, 2023 · BioCardia Reports First Quarter 2023 Business Highlights and Financial Results. BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications. BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...

mediaphotos. BioCardia (NASDAQ:BCDA) signed an agreement to provide its catheter biotherapeutic delivery product candidates for BlueRock Therapeutics' cell therapy products to treat heart failure ...BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector include Apellis Pharmaceuticals APLS, Avid Bioservices CDMO and Biohaven BHVN, also ...Richard Krasno, Ph.D. was appointed to our board of directors in October 2016. Dr. Krasno has served as a director of OPKO Health, Inc. since 2017. Dr. Krasno previously served as a director on the board of Ladenburg Thalmann from 2006 until 2020 and Castle Brands, Inc. from 2014 until 2019. Dr.

BioCardia announces $1.3M registered direct offering priced at-the-market. The Fly • 17 days ago. Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.

BioCardia Inc (BCDA) stock is trading at $2.16 as of 10:19 AM on Friday, Jun 9, an increase of $0.04, or 1.89% from the previous closing price of $2.12. The stock has traded between $2.15 and $2.18 so far today. Volume today is light. So far 5,707 shares have traded compared to average volume of 41,498 shares.Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...Find the latest BioCardia, Inc. (BCDA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...

SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?The estimated Net Worth of Peter Altman is at least $747 Mille dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $69,056 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer e Director at BioCardia.Get the latest BioCardia, Inc. (BCDA) stock news and headlines to help you in your trading and investing decisions. ... 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS ...Most recently, on Friday, May 26th, Peter Altman bought 6,200 shares of BioCardia stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $9,920.00. Following the completion of the transaction, the chief executive officer now directly owns 469,239 shares of the company's stock, valued at $750,782.40.2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval. 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules.

Biocardia Inc stock price (BCDA) NASDAQ: BCDA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today …Stock Price Forecast. According to 1 stock analyst, the 12-month stock price forecast for BioCardia stock is $4.00, which predicts an increase of 543.92%. On average, analysts rate BioCardia stock as a strong buy.15 Nov 2023 ... BioCardia Inc (BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02.Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ... On average, BioCardia executives and independent directors trade stock every 41 days with the average trade being worth of $320,009. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 16 December 2022, trading 595,238 units of BCDA stock currently worth $1,000,000.

Joseph Pantginis, an analyst from H.C. Wainwright, has initiated a new Buy rating on BioCardia ().. Joseph Pantginis’ Buy rating for BioCardia’s stock (BCDA) is based on a combination of ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

BCDA | Complete BioCardia Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest 23andMe Holding Co. (ME) stock quote, history, news and other vital information to help you with your stock trading and investing.A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ...BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...In conclusion, BioCardia Inc’s soaring stock price can be attributed to the FDA’s approval of the Phase 3 CardiAMP Heart Failure II study protocol. This approval has generated optimistic expectations for the company’s future advancements in the treatment of ischemic heart failure.The estimated Net Worth of Peter Altman is at least $875 mil dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $197,402 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer y Director at BioCardia.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%?SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

The estimated Net Worth of Richard M Krasno is at least $410 millier dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $140,000 and over the last 16 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.

Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...

BioCardia Inc. () Stock Market info Recommendations: Buy or sell BioCardia stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the BioCardia share forecasts, stock quote and buy / sell signals below.According to present data BioCardia's BCDA shares and potentially its market environment have been in bearish …Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, …Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple. wise. Select a currency. USD. NASDAQ: Biocardia Inc ( BCDA) = 0.71 USD. Provided by Alpha Vantage.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 17d Why Beyond Air Shares Are Trading Lower By Around 37%?BioCardia Inc ( BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02. BCDA's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 123 out of 146 industries, the …Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...Nov 16, 2023 · BioCardia, Inc. announced a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share in a registered direct offering. July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ...Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,450,986 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!BioCardia ®, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for the CardiAMP ® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac …

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...(g) “Common Stock” means the Common Stock of BioCardia, Inc. (h) “Company” means BioCardia, Inc., a Delaware corporation. (i) “Consultant” means any person who is engaged by the Company or any Parent or Subsidiary to render consulting or advisory services to such entity. (j) “Director” means a member of the Board.Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple. wise. Select a currency. USD. NASDAQ: Biocardia Inc ( BCDA) = 0.71 USD. Provided by Alpha Vantage.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor …Instagram:https://instagram. ftabxvision insurance idahobest mortgage lenders in kentuckytroweprice growth stock fund What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ... c3.ai stock chart4basebio Full Company Report for BCDA. View BioCardia, Inc BCDA investment & stock information. Get the latest BioCardia, Inc BCDA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ... vir biotechnology stocktwits Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.. The largest trade Allan's ever made was buying 20,000 units of BioCardia stock on 21 …Peter Altman owns over 600 units of BioCardia stock worth over $61,795 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia. Wallmine is a radically better financial terminal. ...Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: Biocardia Inc (BCDA) = 0.68 USD. Provided by Alpha Vantage. Biocardia Inc stock (BCDA) in USD.